8-K: Enerpac Tool Group Reports Q1 FY26 Results, Maintains Outlook

Enerpac Tool Group Corp. announced first quarter fiscal 2026 results, reporting a 1% net sales decrease to $144 million, while maintaining its full-year fiscal 2026 guidance.

Summary

• Net sales for the first quarter of fiscal 2026 were $144.2 million, a 1% decrease compared to the prior year, with organic sales declining 2% year-over-year.
• Net earnings were $19.1 million, or $0.36 per diluted share, down from $21.7 million and $0.40 per diluted share in the prior-year period.
• Adjusted EBITDA was $32.4 million, a decrease from $34.3 million in the prior-year period, with adjusted EBITDA margin declining 120 basis points to 22.4%.
• Operating cash flow significantly increased to $16 million, up from $9 million in the prior year.
• The company repurchased approximately 377,000 shares of its common stock for a total of $14.9 million during the quarter.
• Net debt to adjusted EBITDA ratio stood at a healthy 0.3x as of November 30, 2025.
• Industrial Tools & Services (IT&S) organic sales declined 3%, primarily due to a 26% decrease in service revenue, particularly in the UK market, while product sales within IT&S increased 4% organically.
• Cortland Biomedical segment demonstrated strong growth, with sales increasing 27% year-over-year.
• Enerpac Tool Group is maintaining its fiscal 2026 outlook, projecting net sales of $635 million to $655 million, organic sales growth of 1% to 4%, adjusted EBITDA of $158 million to $168 million, adjusted EPS of $1.85 to $2.00, and free cash flow of $100 million to $110 million.

Sentiment

Score: 6

Explanation: The company reported a slight decline in sales and earnings but met internal expectations and maintained its full-year guidance. Strong cash flow and share repurchases are positive, but organic sales decline and specific market softness are areas of concern. The overall sentiment is neutral to slightly positive due to meeting expectations and strong cash generation despite revenue/profit dip.

Positives

• Operating cash flow increased significantly to $16 million from $9 million in the prior year, demonstrating strong cash generation.
• The company reported solid sales growth, particularly in the Americas, and even stronger order growth, indicating underlying demand in key regions.
• Cortland Biomedical segment achieved robust 27% sales growth, highlighting success in a specialized market.
• The net debt to adjusted EBITDA ratio remains very low at 0.3x, indicating a strong balance sheet and low leverage.
• Approximately $15 million was returned to shareholders through share repurchases, reflecting confidence in the company's valuation and commitment to shareholder returns.

Negatives

• Net sales decreased by 1% to $144.2 million compared to the prior-year period.
• Organic sales declined 2% year-over-year, indicating a contraction in core business without currency or acquisition impacts.
• Net earnings decreased to $19.1 million from $21.7 million in the prior-year period.
• Diluted EPS decreased to $0.36 from $0.40 in the prior-year period.
• Adjusted EBITDA decreased to $32.4 million from $34.3 million in the prior-year period.
• Adjusted EBITDA margin declined 120 basis points year-over-year to 22.4%, attributed to lower gross margin and slight deleveraging of operating expenses on lower sales.
• Industrial Tools & Services (IT&S) organic sales declined 3%, primarily driven by a significant 26% decline in service revenue due to softness in the UK market.

Risks

• General economic uncertainty.
• Impact of geopolitical activity, including armed conflicts in the Middle East (and its impact on shipping) and the invasion of Ukraine by Russia (and international sanctions).
• Market conditions in the industrial, oil & gas, energy, power generation, infrastructure, commercial construction, truck, and automotive industries.
• Supply chain risks, including disruptions in deliveries from suppliers due to political tensions and armed conflicts.
• Impacts from the imposition, or threat of imposition, of tariffs and other trade restrictions.
• The ability of the Company to achieve its plans or objectives related to its growth strategy.
• Market acceptance of existing and new products.
• Market acceptance of price increases.
• Successful integration of acquisitions.
• The impact of dispositions and restructurings.
• The ability of the Company to continue to achieve or maintain operational improvements related to the ASCEND program and other restructuring actions.
• Operating margin risk due to competitive pricing and operating efficiencies.
• Risks related to reliance on independent agents and distributors for the distribution and service of products.
• Material, labor, or overhead cost increases.
• Tax law changes.
• Foreign currency risk.
• Interest rate risk.
• Commodity risk.
• Litigation matters.
• Cybersecurity risk.
• Impairment of goodwill or other intangible assets.
• The Company's ability to access capital markets.

Future Outlook

The Company is maintaining its fiscal 2026 outlook, projecting net sales between $635 million and $655 million, with organic sales growth of 1% to 4%. Adjusted EBITDA is forecasted to be $158 million to $168 million, adjusted EPS between $1.85 and $2.00, and free cash flow of $100 million to $110 million. This guidance is based on the Company's key foreign exchange rate assumptions and assumes no substantial change to the current tariff or regulatory environment.

Management Comments

• "Our first quarter results were essentially as expected." Paul Sternlieb, Enerpac Tool Group's President & CEO.
• "We were encouraged by some favorable developments and trends in the quarter for our products, including solid sales growth, particularly in the Americas, and even stronger order growth, reinforcing our cautiously optimistic posture entering 2026." Paul Sternlieb, Enerpac Tool Group's President & CEO.

Industry Context

The results reflect a mixed environment, with strong growth in specific segments like Cortland Biomedical and the Americas, contrasting with softness in other areas such as the UK service market. The company's "cautiously optimistic posture" suggests awareness of ongoing market uncertainties, aligning with broader industrial sector trends that can be impacted by geopolitical events and supply chain dynamics. The continued focus on share repurchases and maintaining a strong balance sheet indicates a prudent financial strategy in a volatile global economic landscape.

Stakeholder Impact

• Shareholders: Impacted by share repurchases ($14.9 million), diluted EPS of $0.36, and maintained fiscal 2026 outlook, suggesting stability.
• Employees: Potential impact from "restructuring actions" mentioned as a general risk factor, though no specific actions or direct impact details are provided in this report.
• Customers: Experience varied conditions, with solid sales growth in the Americas but softness in the UK service market, indicating regional and segment-specific demand dynamics.
• Creditors: The net debt to adjusted EBITDA ratio of 0.3x indicates a healthy leverage position, suggesting low risk for creditors.

Next Steps

• Host an investor conference call on December 18, 2025, at 7:30 am CT to discuss Q1 fiscal 2026 results.
• Continue to execute on fiscal 2026 outlook, projecting net sales of $635 million to $655 million and adjusted EBITDA of $158 million to $168 million.

Key Dates

Recommendation

The company's Q1 fiscal 2026 results were "essentially as expected" and it maintained its full-year guidance, suggesting stability. While net sales and earnings saw a slight decline, strong operating cash flow and a low net debt-to-EBITDA ratio demonstrate financial health. Share repurchases are a positive for shareholders. However, the organic sales decline and specific market softness (UK service market) warrant caution. The outlook is stable but not indicative of significant acceleration, leading to a 'hold' recommendation as the company navigates mixed market conditions while executing its strategy.

Keywords

Enerpac Tool Group, EPAC, Q1 Fiscal 2026, Financial Results, Earnings, Net Sales, Adjusted EBITDA, Share Repurchase, Industrial Tools, Services, Cortland Biomedical, Operating Cash Flow, SEC Filing, 8-K